US STOCKS-Futures firm with focus on Fed, earnings rush

(For a live blog on the U.S. stock market, click LIVE/ or
type LIVE/ in a news window)
* Futures up: Dow 0.41%, S&P 0.46%, Nasdaq 0.78%

By Medha Singh and Devik Jain
July 27 (Reuters) - U.S. stock futures rose on Monday after
a two-day slide for Wall Street, as bets on a more dovish
outlook from the U.S. Federal Reserve brightened the mood ahead
of a busy week for quarterly earnings reports from companies
including Boeing and Apple.
The S&P 500 and Dow logged their first weekly decline in
four on Friday, following concerns over escalating coronavirus
cases in southern and western U.S. states, rising tensions
between the U.S. and China, and data that showed a recovery in
the U.S. job market unexpectedly stalled. Trillions of dollars in fiscal and monetary stimulus have
been pivotal in bringing the S&P 500 to within 5% of its record
high in hit February.
While no major announcements are expected at the end of the
U.S. central bank's two-day meeting on Wednesday, analysts
expect policymakers to lay the groundwork for more action in
September or in the fourth quarter. Investors are also keeping a close watch on progress over
the next round of government aid with less than a week before
enhanced unemployment benefits expire.
Top aides to President Donald Trump said they agreed in
principle with Senate Republicans on a $1 trillion coronavirus
relief package, which will now be negotiated with Democrats.
Earnings reports will also be a major focus this week with
189 companies from the S&P 500 companies expected to report
results, including Boeing Co BA.N , Pfizer Inc PFE.N ,
Facebook Inc FB.O , Apple Inc AAPL.O , Amazon.com Inc AMZN.O
and Alphabet Inc GOOGL.O .
At 6:15 a.m. ET, Dow e-minis 1YMcv1 were up 109 points, or
0.41%, S&P 500 e-minis EScv1 were up 14.75 points, or 0.46%
and Nasdaq 100 e-minis NQcv1 were up 81.5 points, or 0.78%.
Investors will get the first glimpse of the second-quarter
U.S. GDP report on Thursday, which is likely to show the economy
contracted by 34% in the three-month period.
Moderna Inc MRNA.O rose 6.9% premarket after the drugmaker
said it had received an additional $472 million from the U.S.
government's Biomedical Advanced Research and Development
Authority (BARDA) to support development of its novel
coronavirus vaccine.